- About Us
- Advisory Board
- Editorial
- Contact Us
- Advertise
- Contact MJH LS
- Do Not Sell My Information
- Terms and Conditions
- Privacy
© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
Buffalo Neuroimaging Analysis Center
BNAC is a leading neuroimaging research center extending the boundaries of knowledge about neurological disease and disorders through innovative research techniques and advanced neuroimaging bioinformatics. BNAC scientists perform pre-clinical and clinical trials as well as patient-centered, investigator-initiated studies with specialization in MS, Parkinson’s Disease, stroke.
Led since 2003 by its Director Robert Zivadinov, MD, Ph.D., the Center is part of the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, State University of New York.
Connect with us:
Latest from Buffalo Neuroimaging Analysis Center
Comparing Reactive Microglia and Astrocytes in Secondary Progressive Multiple Sclerosis
April 25, 2022
Video
Robert Zivadinov, MD, PhD, discusses the design of a novel comparative study assessing the effect of siponimod (Mayzent; Novartis) and ocrelizumab (Ocrevus; Genentech) on microglia and astrocytes in patients with SPMS.
Understanding the Relationship Between Cerebral Arterial Blood Flow and Serum Neurofilament Light in MS
April 07, 2022
Article
Dejan Jakimovski, MD, PhD, research assistant professor, Buffalo Neuroimaging Analysis Center, discussed his presentation at AAN 2022 on the associations between cerebral hypoperfusion and increased axonal pathology in MS.
The DeepGRAI Registry in Multiple Sclerosis
April 04, 2022
Video
Robert Zivadinov, MD, PhD, offers his insight into the findings from the DeepGRAI registry of thalamic volume measurement on multicenter clinical-quality T2-FLAIR images in multiple sclerosis.
Next Steps in Understanding Cognitive Decline in Aging MS: Dejan Jakimovski, MD, PhD
January 11, 2022
Video
The research assistant professor at the Buffalo Neuroimaging Analysis Center provided context on how different forms of multiple sclerosis impact cognitive decline in patients. [WATCH TIME: 4 minutes]
MS Disease-Modifying Therapy Discontinuation Associated With Disability Progression
January 05, 2022
Article
DMT discontinuation resulted with new disability worsening and/or progression in previously stable patients with relapsing-remitting MS and particularly in patients with previously stable secondary progressive MS.
NeuroVoices: Dejan Jakimovski, MD, PhD, on the Need to Address Cognitive Decline in an Aging MS Population
January 05, 2022
Article
The research assistant professor at the Buffalo Neuroimaging Analysis Center discussed the importance of continued research on how patients with multiple sclerosis experience cognitive decline as they age.